Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Solasia Pharma KK ( (JP:4597) ) has provided an announcement.
Solasia Pharma K.K. announced a fundraising initiative through the issuance of warrants to Macquarie Bank Limited, aiming to raise JPY 2,049 million. The funds will be used to resume the development of SP-05, a colorectal cancer treatment, after previous clinical trials did not meet primary endpoints. The decision to continue development follows a reanalysis by Isofol Medical AB, the licensor of SP-05, which led to the resumption of clinical trials. This move is expected to enhance Solasia’s position in the oncology market and potentially bring a new treatment option for colorectal cancer.
More about Solasia Pharma KK
Solasia Pharma K.K. is a specialty pharmaceutical company based in Asia, primarily focused on developing treatments for cancer. The company is headquartered in Tokyo, Japan, and is involved in the development of pharmaceuticals and medical devices, with a market focus on oncology.
YTD Price Performance: 18.13%
Average Trading Volume: 271
Technical Sentiment Signal: Hold
Current Market Cap: €55.1M
Learn more about 4597 stock on TipRanks’ Stock Analysis page.